Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 253

1.

Functional status in a geriatric oncology setting: A review.

Couderc AL, Boulahssass R, Nouguerède E, Gobin N, Guérin O, Villani P, Barlesi F, Paillaud E.

J Geriatr Oncol. 2019 Feb 26. pii: S1879-4068(18)30280-7. doi: 10.1016/j.jgo.2019.02.004. [Epub ahead of print] Review.

PMID:
30824222
2.

[Tumor banks and complex data management: Current and future challenges].

Hofman P, Dagher G, Laurent-Puig P, Marquette CH, Barlesi F, Bibeau F, Clément B.

Ann Pathol. 2019 Feb 25. pii: S0242-6498(19)30033-1. doi: 10.1016/j.annpat.2019.01.017. [Epub ahead of print] French.

PMID:
30819623
3.

Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

Levy B, Paz-Ares L, Bennouna J, Felip E, Abreu DR, Isla D, Barlesi F, Molinier O, Madelaine J, Audigier-Valette C, Kim SW, Kim HR, Ozguroglu M, Erman M, Badin FB, Mekhail TM, Scheff R, Chisamore MJ, Sadrolhefazi B, Riess JW.

Clin Lung Cancer. 2019 Jan 4. pii: S1525-7304(19)30001-4. doi: 10.1016/j.cllc.2018.12.022. [Epub ahead of print]

4.

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases.

Tomasini P, Egea J, Souquet-Bressand M, Greillier L, Barlesi F.

Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619831906. doi: 10.1177/1753466619831906.

5.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso PM, Burris HA, Gordon MS, Bang YJ, Hellmann MD, Cervantes A, Ochoa de Olza M, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott DF, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey KM, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Feb 15. pii: clincanres.2740.2018. doi: 10.1158/1078-0432.CCR-18-2740. [Epub ahead of print]

PMID:
30770348
6.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, Chaleat S, Khobta N, Milia J, Mhanna L, Greillier L, Biemar J, Nanni I, Ouafik L, Garcia S, Mazières J, Barlesi F, Mascaux C.

J Thorac Oncol. 2019 Feb 6. pii: S1556-0864(19)30040-1. doi: 10.1016/j.jtho.2019.01.011. [Epub ahead of print]

PMID:
30738221
7.

Health-Related Quality of Life in KEYNOTE-010: a Phase 2/3 Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, PD-L1-Expressing NSCLC.

Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G Jr, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS.

J Thorac Oncol. 2019 Jan 31. pii: S1556-0864(19)30091-7. doi: 10.1016/j.jtho.2019.01.016. [Epub ahead of print]

PMID:
30711649
8.

Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.

Reck M, Horn L, Novello S, Barlesi F, Albert I, Juhász E, Kowalski D, Robinet G, Cadranel J, Bidoli P, Chung J, Fritsch A, Drews U, Wagner A, Govindan R.

J Thorac Oncol. 2019 Jan 21. pii: S1556-0864(19)30029-2. doi: 10.1016/j.jtho.2019.01.010. [Epub ahead of print]

PMID:
30677506
9.

Efficacy and safety of nivolumab in patients with non-small cell lung cancer: a retrospective study in clinical practice.

Montana M, Garcia ME, Ausias N, Jeanpierre M, Meiffren M, Giorgi R, Vanelle P, Barlesi F.

J Chemother. 2018 Dec 30:1-5. doi: 10.1080/1120009X.2018.1551753. [Epub ahead of print]

PMID:
30595104
10.

"I think it's a bit early for now": impact of psychological factors on drafting advance directives among cancer patients.

Cannone P, Tomasini P, Paul M, Barlesi F, Dany L.

J Psychosoc Oncol. 2018 Dec 26:1-13. doi: 10.1080/07347332.2018.1541494. [Epub ahead of print]

PMID:
30585529
11.

The clinical utility of tumor mutational burden in non-small cell lung cancer.

Greillier L, Tomasini P, Barlesi F.

Transl Lung Cancer Res. 2018 Dec;7(6):639-646. doi: 10.21037/tlcr.2018.10.08. Review.

12.

Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.

Jeanson A, Boyer A, Greillier L, Tomasini P, Barlesi F.

Expert Rev Anticancer Ther. 2018 Dec 4:1-7. doi: 10.1080/14737140.2019.1554440. [Epub ahead of print]

PMID:
30513023
13.

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.

Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, Boucekine M, Mascaux C, Barlesi F.

Clin Lung Cancer. 2018 Oct 11. pii: S1525-7304(18)30263-8. doi: 10.1016/j.cllc.2018.10.002. [Epub ahead of print]

PMID:
30442524
14.

Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care.

Patel JD, Paz-Ares L, Zinner RG, Barlesi F, Koustenis AG, Obasaju CK.

Clin Lung Cancer. 2018 Nov;19(6):e823-e830. doi: 10.1016/j.cllc.2018.05.013. Epub 2018 May 26. Review.

PMID:
30369427
15.

Specialists to the Rescue of Oncologists for the Management of Toxicity Occurring Under Combination of Anticancer Therapies.

Chevalier T, Burtey S, Barlesi F.

J Thorac Oncol. 2018 Nov;13(11):e231-e232. doi: 10.1016/j.jtho.2018.07.003. No abstract available.

PMID:
30368416
16.

[Autoimmune-related bleeding occurring during combined immunotherapy for lung cancer - Case report].

Eberst G, Lakhzoum W, Tomasini P, Andreotti N, Abcaya J, Mascaux C, Barlesi F.

Rev Mal Respir. 2018 Nov;35(9):974-977. doi: 10.1016/j.rmr.2018.01.013. Epub 2018 Oct 11. French.

PMID:
30318433
17.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, Özgüroğlu M, Szczesna A, Polychronis A, Uslu R, Krzakowski M, Lee JS, Calabrò L, Arén Frontera O, Ellers-Lenz B, Bajars M, Ruisi M, Park K.

Lancet Oncol. 2018 Nov;19(11):1468-1479. doi: 10.1016/S1470-2045(18)30673-9. Epub 2018 Sep 24. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30262187
18.

ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?

Cabillic F, Hofman P, Ilie M, Peled N, Hochmair M, Dietel M, Von Laffert M, Gosney JR, Lopez-Rios F, Erb G, Schalles U, Barlesi F.

ESMO Open. 2018 Sep 17;3(6):e000419. doi: 10.1136/esmoopen-2018-000419. eCollection 2018.

19.

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.

Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L.

J Thorac Oncol. 2018 Dec;13(12):1906-1918. doi: 10.1016/j.jtho.2018.08.2027. Epub 2018 Sep 11.

PMID:
30217492
20.

Immunologically effective dose: a practical model for immuno-radiotherapy.

Serre R, Barlesi F, Muracciole X, Barbolosi D.

Oncotarget. 2018 Aug 7;9(61):31812-31819. doi: 10.18632/oncotarget.25746. eCollection 2018 Aug 7.

21.

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV.

Oncologist. 2018 Aug 23. pii: theoncologist.2018-0089. doi: 10.1634/theoncologist.2018-0089. [Epub ahead of print]

PMID:
30139835
22.

Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study.

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Oct;124:310-316. doi: 10.1016/j.lungcan.2018.07.042. Epub 2018 Aug 10.

23.

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).

Bennouna J, Barlesi F, Do P, Dumont P, Cadranel J, Debieuvre D, Hilgers W, Molinier O, Quoix E, Raimbourg J, Langlais A, Morin F, Souquet PJ.

ESMO Open. 2018 Jul 23;3(5):e000394. doi: 10.1136/esmoopen-2018-000394. eCollection 2018.

24.

Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.

Cho BC, Dy GK, Govindan R, Kim DW, Pennell NA, Zalcman G, Besse B, Kim JH, Koca G, Rajagopalan P, Langer S, Ocker M, Nogai H, Barlesi F.

Lung Cancer. 2018 Sep;123:14-21. doi: 10.1016/j.lungcan.2018.04.022. Epub 2018 Apr 27.

25.

Lamins in Lung Cancer: Biomarkers and Key Factors for Disease Progression through miR-9 Regulation?

Guinde J, Frankel D, Perrin S, Delecourt V, Lévy N, Barlesi F, Astoul P, Roll P, Kaspi E.

Cells. 2018 Jul 16;7(7). pii: E78. doi: 10.3390/cells7070078. Review.

26.

Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I.

Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007. Epub 2018 Jun 9.

27.

Another Drawback for Clinical Trials Entry Criteria.

Andriantsoa M, Barbolosi M, Barlesi F.

J Thorac Oncol. 2018 Jul;13(7):e116-e117. doi: 10.1016/j.jtho.2018.02.007. No abstract available.

PMID:
29935847
28.

Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times.

Loubière S, Barlesi F, Missy P, Morin F, Auquier P, Cadranel J.

Eur Respir J. 2018 Jun 21;51(6). pii: 1800844. doi: 10.1183/13993003.00844-2018. Print 2018 Jun. No abstract available.

PMID:
29929958
29.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR.

J Thorac Oncol. 2018 Sep;13(9):1248-1268. doi: 10.1016/j.jtho.2018.05.030. Epub 2018 Jun 6. Review.

PMID:
29885479
30.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group.

N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.

31.

Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.

Tomasini P, Greillier L, Boyer A, Jeanson A, Barlesi F.

J Thorac Dis. 2018 Apr;10(Suppl 9):S1032-S1036. doi: 10.21037/jtd.2018.04.61. No abstract available.

32.

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.

Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F.

J Thorac Oncol. 2018 Aug;13(8):1156-1170. doi: 10.1016/j.jtho.2018.04.039. Epub 2018 May 17. Erratum in: J Thorac Oncol. 2018 Nov;13(11):1800.

PMID:
29777823
33.

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.

Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).

Eur Respir J. 2018 Mar 15;51(3). pii: 1701467. doi: 10.1183/13993003.01467-2017. Print 2018 Mar.

PMID:
29545318
34.

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C.

Eur Respir Rev. 2018 Mar 14;27(147). pii: 170098. doi: 10.1183/16000617.0098-2017. Print 2018 Mar 31. Review.

35.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B.

ERJ Open Res. 2018 Feb 13;4(1). pii: 00058-2017. doi: 10.1183/23120541.00058-2017. eCollection 2018 Jan.

36.

Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy.

Jean F, Tomasini P, Barlesi F.

Ther Adv Med Oncol. 2017 Dec;9(12):769-779. doi: 10.1177/1758834017741074. Epub 2017 Dec 19. Review.

37.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.

von Pawel J, Spigel DR, Ervin T, Losonczy G, Barlesi F, Juhász E, Anderson M, McCall B, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Reck M.

Oncologist. 2018 Jun;23(6):654-e58. doi: 10.1634/theoncologist.2017-0690. Epub 2018 Feb 7.

38.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.

Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G Jr, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crinò L.

Ann Oncol. 2018 Apr 1;29(4):959-965. doi: 10.1093/annonc/mdy041.

PMID:
29408986
39.

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulou V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F.

Clin Lung Cancer. 2018 Jul;19(4):301-314. doi: 10.1016/j.cllc.2017.12.010. Epub 2017 Dec 22. Review.

PMID:
29396237
40.

Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid.

Frankel D, Nanni-Metellus I, Robaglia-Schlupp A, Tomasini P, Guinde J, Barlesi F, Astoul P, Ouafik L, Amatore F, Secq V, Kaspi E, Roll P.

Clin Chem Lab Med. 2018 Apr 25;56(5):748-753. doi: 10.1515/cclm-2017-0527.

PMID:
29306909
41.

Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB.

J Thorac Oncol. 2018 Apr;13(4):576-584. doi: 10.1016/j.jtho.2017.11.131. Epub 2017 Dec 13.

PMID:
29247830
42.

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.

Imbs DC, El Cheikh R, Boyer A, Ciccolini J, Mascaux C, Lacarelle B, Barlesi F, Barbolosi D, Benzekry S.

CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):42-50. doi: 10.1002/psp4.12265. Epub 2017 Dec 7.

43.

Clustering based on unsupervised binary trees to define subgroups of cancer patients according to symptom severity in cancer.

Michel P, Hamidou Z, Baumstarck K, Ghattas B, Resseguier N, Chinot O, Barlesi F, Salas S, Boyer L, Auquier P.

Qual Life Res. 2018 Feb;27(2):555-565. doi: 10.1007/s11136-017-1760-9. Epub 2017 Dec 8.

PMID:
29218507
44.

Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.

Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, Monestier S, Grob JJ, Scemama U, Jacquier A, Lalevee N, Barraud J, Peyrol M, Laine M, Bonello L, Paganelli F, Cohen A, Barlesi F, Ederhy S, Thuny F.

Circulation. 2017 Nov 21;136(21):2085-2087. doi: 10.1161/CIRCULATIONAHA.117.030571. No abstract available.

PMID:
29158217
45.

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.

Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI.

Br J Cancer. 2018 Jan;118(1):38-42. doi: 10.1038/bjc.2017.395. Epub 2017 Nov 16.

46.

Personalised medicine for nonsmall cell lung cancer.

Mascaux C, Tomasini P, Greillier L, Barlesi F.

Eur Respir Rev. 2017 Nov 15;26(146). pii: 170066. doi: 10.1183/16000617.0066-2017. Print 2017 Dec 31. Review.

47.

Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.

Capelle H, Tummino C, Greillier L, Gouitaa M, Birnbaum J, Ausias N, Barlesi F, Montana M.

J Clin Pharm Ther. 2018 Jun;43(3):320-326. doi: 10.1111/jcpt.12645. Epub 2017 Nov 1.

PMID:
29092096
48.

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE.

J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.

49.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT).

Ann Oncol. 2017 Nov 1;28(11):2715-2724. doi: 10.1093/annonc/mdx404.

PMID:
28945865
50.

A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer.

Katakami N, Felip E, Spigel DR, Kim JH, Olivo M, Guo M, Nokihara H, Yang JC, Iannotti N, Satouchi M, Barlesi F.

Ann Oncol. 2017 Sep 1;28(9):2241-2247. doi: 10.1093/annonc/mdx284.

Supplemental Content

Loading ...
Support Center